Current approaches to management of patients with mild cognitive impairment

Zakharov V.V.; Gromova D.O.

doi:https://doi.org/10.17116/jnevro201711731107-112

Zakharov V.V.

Sechenov First Moscow State Medical University, Moscow, Russia

Gromova D.O.

Sechenov First Moscow State Medical University, Moscow, Russia

Current approaches to management of patients with mild cognitive impairment

Authors:

Zakharov V.V., Gromova D.O.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3): 107‑112

DOI: 10.17116/jnevro201711731107-112

Read: 2075 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zakharov VV, Gromova DO. Current approaches to management of patients with mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):107‑112. (In Russ.)
https://doi.org/10.17116/jnevro201711731107-112

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Activation of endogenous mechanisms of sanogenesis in cognitive impairment in cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):7-13

Cognitive impairment in bilinguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

The relationship between neuropsychological indicators and neuroimaging changes according to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;(10):72-83

Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;(11):85-93

Differentiated approach to cognitive rehabilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11

Abstract:

Mild cognitive impairment (MCI) is an intermediate stage between normal aging and dementia. The prevalence of MCI among elderly people is 12-17% but the risk of progression of cognitive impairment and development of dementia during 5 years is up to 70%. Cerebral vascular diseases and initial stages of neurodegenerative processes are the cause of MCI. Clinical characteristics of MCI depend on the main etiological factor. To decrease the severity of symptoms and prevent the progression of cognitive impairment in MCI patients, pharmacotherapy and non-medication methods, including diet optimization, stimulation of mental and physical activity, are used. Dopaminergic and noradrenergic therapy is most prevalent among pharmacological methods.

Keywords:

cognitive impairment

mild cognitive impairment

prevention of dementia

neuroprotective therapy

Authors:

Zakharov V.V.

Sechenov First Moscow State Medical University, Moscow, Russia

Gromova D.O.

Sechenov First Moscow State Medical University, Moscow, Russia

Close metadata

References:

Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013 Accessed 29.11.2016. Availiable at: http://www.dsm5.org/Pages/Default.aspx
Zakharov VV. Moderate cognitive disorders as a multidisciplinary problem. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(2):5-10. (In Russ.). doi: 10.14412/2074-2711-2010-77
Golomb J, Kluger A, Garrard P, Ferris S. Clinician's Manual on Mild Cognitive Impairment. London, UK: Science Press; 2001.
Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349(9068):1793-1796. doi.org/10.1016/s0140-6736(97)01007-6
Petersen RS, Smith GE, Waring SC, Ivnik RJ, Tangalos EJ, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology. 1999;56(3):303-308. doi: 10.1001/archneur.56.3.303
Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133-1142. doi.org/10.1212/wnl.56.9.1133
Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: A population-based validation study. Neurology. 2001;56(1):37-42. http://dx.doi.org/10.1212/WNL.56.1.37
Petersen RC, Negash S. Mild cognitive impairment: An Overview. CNS Spectrums. 2008;13(1):45-53. https://doi.org/10.1017/S1092852900016151
Petersen RC Mild cognitive impairment: useful or not? Alzheimer’s & Dementia. 2005;1(1):5-10. https://doi.org/10.1016/j.jalz.2005.06.013
Di Carlo A., Baldereschi M., Amaducci L., Maggi S., Grigoletto F., Scarlato G., Inzitari D. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. Journal of the American Geriatrics Society. 2000;48(7):775-782. https://doi.org/10.1111/j.1532-5415.2000.tb04752.x
The Montreal Cognitive Assessment (MoCA). 2010. Accessed 29.11.2016. Availiable at: www.mocatest.org
Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Stepkina DA, Lokshina AB, Mkhitaryan EA, Koberskaya NN, Savushkina IY. Prevalence of cognitive impairments in neurological diseases: Analysis of the activities of a specialized outpatient reception office. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):30-35. (In Russ.). doi: 10.14412/2074-2711-2012-378
Zakharov VV, Yakhno NN. Memory impairments. М.: Geotar Мed; 2003. (In Russ.).
Yakhno NN, Zakharov VV, Lokshina AB. Moderate cognitive dysfunction syndrome in dyscirculatory encephalopathy. Zhurnal nevrologii I psikhiatrii im. S.S. Korsakova. 2005;105(2):13-17. (In Russ.).
Yakhno NN. Cognitive impairment in neurologic clinic. The neurological journal. 2006;11:(suppl 1):4-12. (In Russ.).
Keyser JD, Herregodts P, Ebinger G. The mesoneocortical dopamine neuron system. Neurology. 1990;40:1660-1662. https://doi.org/10.1212/wnl.40.11.1660
Aston-Jones G, Rajkowsky J, Cohen J. Role of locus coeruleus in attention and behavioral flexibility. Biological physchiatry. 1999;46(9):1309-1320. http://dx.doi.org/10.1016/S0006-3223(99)00140-7
Bäckman L, Ginovart N, Dixon RA, Robins Wahlin T, Wakhlin Å, Halldin C, Farde L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. American Journal of Psychiatry. 2000;157(4):635-637. http://dx.doi.org/10.1176/ajp.157.4.635
Volkow N, Wang G, Fowler J, Ding YS, Gur RC, Gatley J, Logan J, Moberg PJ, Hitzemann R, Smith G, Pappas N. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Annals of neurology. 1998;44(1):143-147. https://doi.org/10.1002/ana.410440125
Bille J, Bukiwsky FV, De Ferron A et al. Decline cerebral et therapeutique: une etude Clinique multicenrique de Trivastal 50 retard en Neuro-Geriatrie. Psych Med. 1986;18:609-626.
Scholing WE. A double-blind study using psychometric tests Trivastal versus a reference compound. Temp Medical. 1982;114.
Nagaraia D, Jayashree S. Randomised study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. American Journal of Psychiatry. 2001;158(9):1517-1519. https://doi.org/10.1176/appi.ajp.158.9.1517
Zakharov VV, Lokshina AB. Use of Pronoran (piribedil) in elderly patients with mild cognitive impairment and dyscirculatory encephalopathy. The neurological journal. 2004;2:30-35. (In Russ.).
Zakharov VV. Prevalence and treatment of cognitive impairment in neurologic clinic (Results of the All-russian trial «Prometej»). CONSILIUM MEDICUM. 2008; 10(2):25-29. (In Russ.).
Yakhno NN, Zakharov VV, Stachunskaya EY, Velmejkin SB, Zhitkova YV, Ivanova IL, Kurushina OV, Pokhabov DV, Svirkunova SA. Treatment of non-dementia cognitive impairment in patients with arterial hypertension and cerebral atherosclerosis (the results of Russian multicenter trial «Fuete»). The neurological journal. 2012;4:49-55. (In Russ.).
Abbott RD, White RD, Ross GW, Masaki KH, Curb DJ, Petrovich H. Walking and dementia in physically capable elderly men. JAMA. 2004;292(12):1447-1453. doi: 10.1001/jama.292.12.1447
Laurin D, Verreault R, Linsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Archives of neurology. 2001;58(3):498-504. https://doi.org/10.1001/archneur.58.3.498
Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S. Effects of Aerobic Exercise on Mild Cognitive Impairment:A Controlled Trial. Archives of neurology. 2010;67(1):71-79. https://doi.org/10.1001/archneurol.2009.307
Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, Bäckman L, Hänninen T, Laatikainen T, Lindström J, Mangialasche F, Nissinen A, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress. 2013;9:657-665. https://doi.org/10.1016/j.jalz.2012.09.012
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet. 2015;385(9984):2255-2263. https://doi.org/10.1016/s0140-6736(15)60461-5